CD4 and pulmonary tuberculosis: Based on the above results, we conclude that rhuIL-2-based adjunctive immunotherapy can expand the proliferation and conversion of CD4+ and NK cells, improve the function of host immunity, and manipulate the evolution and progression of pulmonary TB.